NextCell Pharma publishes Interim Report 2 2021/2022

April 28, 2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website:https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Second quarter (2021-12-01 until 2022-02-28)

● Operating income amounted to 1 840 (1 008) TSEK.
● Operating result amounted to -10 212 (-8 149) TSEK.
● Earnings per share* amounted to -0,30 (-0,27) SEK.
● Cash and bank amounted to 118 170 (148 936) TSEK.
● Solidity** amounted to 94,3 (96,8) %.

First half-year (2021-09-01 till 2022-02-28)

● Operating income amounted to 3 187 (2 141) TSEK.
● Operating result amounted to -16 906 (-13 678) TSEK.
● Earnings per share* amounted to -0,22 (-0,51) SEK.
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523 (29,717,519) shares. Average number of shares for the first half year 2021/2022: 34,379,523 (26,540,470) shares. Number of shares in NextCell as of February 28, 2022: 34,379,523 (33,712,857) shares. **Solidity: Own capital's share of the sheet total

‍

Significant events in the second quarter

● NextCell announced in December that it has entered into a cooperation agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects in support of everyone living with and around T1D. Together we want to spread hope fortype 1 diabetes research and make NextCell's clinical trials visible.
● NextCell announced in January that the company's CEO, Mathias Svahn, had been invited to give a presentation about the company's journey in cell therapy at the Advanced Therapy Week in Miami, USA at the end of January.
● NextCell announced in early February that the company had increased its involvement in FamiCordTx, a joint venture in cell and gene therapy, in a new share issue by approximately 160 kEUR.
● NextCell announced in mid-February that a Pediatric Diabetes Study is underway and that the company is contributing ProTrans and placebo.
● NextCell announced at the end of February that the Canadian probation for ProTrans in COVID-19 will be expanded to a multicenter study
● NextCell announced at the end of October that the clinical trial ProTrans19+SE can begin recruiting patients in the mean dose group. Three patients treated with a low dose of ProTrans have been clinically evaluated and the data have been reviewed by the Safety Committee, which now allows continued medium-dose treatment of ProTrans for severe pneumonia caused by COVID-19.

Significant events after the reporting period

● NextCell announced in early April that the stem cell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in cellovia's biobank, suffers from a serious blood disorderto be treated with stem cells at the Hematology Department at Rigshospitalet.
● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 28-04-2022 08:00 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Instagram: https://www.instagram.com/cellaviva/

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO)

Download attachment Read full press release on Cision (external link)

2019-07-31

Interim report 2018-09-01 - 2019-05-31

Third quarter report By "NextCell", “NXTCL” or "Company" is meant NextCell Pharma AB with organization number 556965-8361. “Spotlight" refers to the Spotlight Stock Market (previous AktieTorget). Amount in brackets refer to the corresponding period in the previous year. Note that the Company's fiscal year is September 1 - August 31. This English version is a translation of the Swedish version. The Swedish version is at all time to be seen as the leading document. Nine months (2018-09-01 until 2019-05-31) · Operating income amounted to SEK 1 410 055 (527 545). · Operating result

Read more Read more

2019-06-20

Final patient treated in the phase II part of the ProTrans-1 trial

NextCell Pharma AB (NextCell) today treated the last diabetic patient in the phase II part of the ProTrans-1 trial. This means that all patients included in the clinical study have been treated and are now subject to a 12-month follow-up period before efficacy and safety data will be available. The final patient has been treated in the randomized, placebo controlled ProTrans-1 phase II part trial. Efficacy and safety data will be collected through regular clinical assessments visits during a 12 month period. Last patient, last will be assessed in July 2020 and thereafter the code will be

Read more Read more

2019-06-20

New collaboration and increased digital presence - Cellaviva is gearing for growth

NextCell Pharma AB ("NextCell") today announces that they, via its biobank Cellaviva, have entered into a partnership with Bonzun Health Information AB ("Bonzun"), who are providing the first global health app for pregnant women. Bonzun has launched the first virtual midwife for pregnant women which can be downloaded in Appstores under the name Bonzun Pregnant. The app is currently available in 79 countries worldwide under the name Bonzun and in Sweden under the name Min Graviditet. The collaboration has been entered into with the common goal of strengthening the work of sharing knowledge

Read more Read more

2019-06-19

NextCell has treated the first patient in the ProTrans-Repeat trial

NextCell Pharma AB (NextCell) announces that earlier today the first patient was treated as part of the ProTrans-Repeat trial, which is NextCell’s second clinical trial. ProTrans-Repeat is a Phase IIa clinical trial which includes patients receiving active treatment with ProTrans and who have previously been treated in the ProTrans-1 study's dose escalation phase. This means that the participants receive their second treatment with ProTrans, just over a year after the first. The goal of the ProTrans-Repeat trial is to test whether repeated treatment can increase or maintain the effect of

Read more Read more

2019-06-11

Anders Essen-Möller subscribes to his entire stakes in NextCell Pharmas right issue

The two largest owners of NextCell Pharma AB (“NextCell” or “The Company”) Anders Essen-Möller and Diamyd Medical AB, fully subscribe for their respective shares in NextCells ongoing rights issue. This means that both parties consolidate their ownership interests and that Essen-Möllers ownership in NextCell after the investments increases from approximately SEK 3.6 million to 6.0 million. Regarding the ongoing rights issue in NextCell, the principal owner Anders Essen-Möller, also the chairman of the company, has chosen to fully utilize its allotted subscription rights, which means that he

Read more Read more

2019-06-05

Selected to participate in the EIT Health Start.Smart.Global (SSG) programme.

NextCell Pharma AB (publ) ("NextCell") has been chosen as one of a select group of companies to participate in the EIT Health Start.Smart.Global (SSG) programme. The programme focusses on helping European life science SMEs successful entries into Japan and South Korea. EIT Health is a Knowledge and Innovation Community established by the European Institute for Innovation & Technology (EIT) (https://eit.europa.eu/), an independent EU body set up to promote innovation and entrepreneurship across Europe. The EIT Health Start.Smart.Global (SSG) programme, helps European life science SMEs

Read more Read more

2019-05-17

NextCell now has two parallel running clinical trials, ProTrans-1 and ProTrans-Repeat which was initiated today

NextCell Pharma AB (NextCell) announces that the initiation meeting for ProTrans-Repeat was held today at Karolinska University Hospital in Huddinge. ProTrans-Repeat is a completely independent trial and has no effect on the ProTrans-1 study. NextCell now has two ongoing clinical trials that run parallel and according to plan. ProTrans-Repeat's Principal investigator Professor Per-Ola Carlsson and the study team from Karolinska Trial Alliance, together with NextCell, went through the last practical details, which means that the new study has now been formally initiated. ProTrans-Repeat means

Read more Read more

2019-05-17

Rectification: Six out of nine patients in the first part of the phase I/II trial, ProTrans-1 have completed treatment

NextCell Pharma AB (NextCell) announces that six out of the nine patients included in the dose escalation part of ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study. Earlier this week, the last of the three patients in the so-called medium-dose-cohort visited for their 12-month follow-up, the final part of the trial, which means that all three now have completed their part of the trial. In early March, the three patients in the low-dose cohort had already completed the trial. This means that six out of nine patients in the phase I part

Read more Read more